Nothing But the TRUth Now: Broad IgAN Label Approval Sets Up Commercial Launch

Research evidence excerpt

Nothing But the TRUth Now: Broad IgAN Label Approval Sets Up Commercial Launch

TD Cowen Vera Therapeutics

Global Research July 7, 2026

TD Cowen disclaims any and all liability relating to the information herein, including without limitation any express or implied representations or warranties for,

statements contained in, and omissions from, the information. TD Cowen is not liable for any errors or omissions in such information or for any loss or damage suffered,

directly or indirectly, from the use of this information. TD Cowen may have effected or may effect transactions for its own account in the securities described herein. No

proposed customer or counterparty relationship is intended or implied between TD Cowen and a recipient of this document.

TD Cowen research is produced in the U.S. by TD Securities (USA) LLC, a wholly owned subsidiary of The Toronto-Dominion Bank. TD Securities (USA) LLC is a U.S.

broker dealer registered with the U.S. Securities and Exchange Commission and is a member of the Financial Industry Regulatory Authority and of the Securities

Investor Protection Corporation.

TD Cowen research is produced in Canada by TD Securities Inc., a wholly owned subsidiary of The Toronto-Dominion Bank. TD Securities Inc. is regulated by the

Canadian Investment Regulatory Organization of Canada, a member of the Canadian Investor Protection Fund and a member of Canadian Marketplaces.

The legal entity identified on the front cover is the legal entity responsible for the production of this report. Where there are multiple authors with different legal entities

identified, these legal entities are jointly responsible for the production of this report. Multiple authors from various TD Securities legal entities may have contributed to